>>> US After Hours Summary: MG +15.9%, EDUC +9.0%, ZUMZ +3.8%, R

After Hours Summary: MG +15.9%, EDUC +9.0%, ZUMZ +3.8%, RELL +5.2%, CSII -19.7%, DB -6.9%, EXFO -1.0% following earnings/guidance

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings: MG +15.9%, EDUC +9.0%, ZUMZ +3.8%, RELL +5.2%, RECN +0.6%

Companies trading higher in after hours in reaction to news: NVLS +16.2% (announced positive Phase 1b results for N91115 in patients with Cystic Fibrosis; plans to initiate Phase 2 Trial in the 4Q15), LL +10.9% (reached a settlement with the DOJ related to compliance with the Lacey Act, regarding the sourcing of timber by foreign suppliers; settlement unrelated to current California Air Resources Board related claims around certain Lumber Liquidators products), JMG +8.4% (WSJ reporting Gannett (GCI) is close to acquiring the company for ~$300 mln), BTX +6.3% (OncoCyte subsidiary filed Registration Statement with the SEC in connection with co's planned distribution OncoCyte common stock to holders of BioTime), MBLX +4.0% (entered into a $20 mln common stock purchase agreement with Aspire Capital Fund), INTL +3.1% (to replace AMSG in the S&P SmallCap 600), SLRC +1.7% (announced a $30 mln repurchase program), AMSG +1.2% (to replace CNW in the S&P MidCap 400), VRTX +1.0% (co's sNDA for the use of KALYDECO in people with cystic fibrosis ages 2 and older accepted by the FDA), RBA +1.0% (reported September gross auction proceeds rose $17 mln, or 3.8% from prior year on a reported basis; Q3 gross auction proceeds rose $8 mln, or 0.9% from prior year on a reported basis)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings: CSII -19.7%, DB -6.9%, EXFO -1.0%

Companies trading lower in after hours in reaction to news: ORIG -12.6% (co announced an update on its fleet, stating 'the market continues to remain challenging due to the massive spending cuts initiated by the oil companies'), PIP -9.9% (announced oral arguments in SIGA's appeal and PharmAthene's cross-appeal have concluded), DB -6.9% (co said it will recommend reduction or possible elimination of dividend following weak Q3), NEWT -3.4% (to launch a public offering of 2 mln shares of common stock), SMG -1.1% (priced $400 mln of 6.000% senior notes due 2023)